Abstract: Methods are disclosed for viable preservation of biomaterials including both prokaryotic and eukaryotic cells/materials such as human cells and tissues at subzero and suprazero temperatures. One embodiment provides a method wherein initial desiccation and subsequent cooling of the biological samples is below their glass transition temperature (Tg) to achieve a stable glassy state without exposing the biomaterials to excessive osmotic/chemical stresses for long periods of time. Another embodiment provides a method that includes combining the initial desiccation with subsequent freeze-drying to achieve a glassy state of biomaterials. Another embodiment provides a desiccation medium with low salt, high osmolyte/glass former content and desiccation of biomaterials in a spherical droplet to avoid the edge effect.

Abstract: A method for the cryopreservation of eggs, nauplii and juvenile of barnacles. Cryopreserved feed and a use of the preserved organisms as live feed organism in marine aquaculture typically replacing rotifers and Artemia and other life feed organisms.

Abstract: The invention includes methods, apparatus, and systems for the conversion of hydrogen together with carbon dioxide or carbon monoxide to methane using a population of microbes and a defined liquid medium. The microbial population maintains the amount of nutrients in the liquid medium within a relative range without requiring replenishment of the nutrients. Methods and apparatus for enriching the microbial population are also described.

Abstract: The present invention relates to compositions comprising low sugar media, the methods of using these compositions to reduce trauma and stress on processed animal sperm, the resulting sperm and embryo products, and the methods of use of these products to increase the quality, quantity and viability of progeny and improved rates of births in animals.

Abstract: Embodiments of the invention relate generally to protein extraction and, more generally, to bone protein extraction methods that do not require demineralization. In one embodiment, the invention provides a method comprising: mixing a bone sample and a quantity of an extraction buffer comprising: ammonium phosphate dibasic; or ammonium phosphate dibasic and ammonium bicarbonate; or ammonium phosphate dibasic, ammonium bicarbonate, and guanidine HCl; or sodium phosphate dibasic and sodium bicarbonate; or sodium phosphate dibasic, sodium bicarbonate, and guanidine HCl; or potassium phosphate dibasic and potassium bicarbonate; or potassium phosphate dibasic, potassium bicarbonate, and guanidine HCl; and incubating the bone sample/extraction buffer mixture.

Abstract: Thin parylene C membranes having smooth front sides and ultrathin regions (e.g., 0.01 ?m to 5 ?m thick) interspersed with thicker regions are disclosed. The back sides of the membranes can be rough compared with the smooth front sides. The membranes can be used in vitro to grow monolayers of cells in a laboratory or in vivo as surgically implantable growth layers, such as to replace the Bruch's membrane in the eye. The thin regions of parylene are semipermeable to allow for proteins in serum to pass through, and the thick regions give mechanical support for handling by a surgeon. The smooth front side allows for monolayer cell growth, and the rough back side helps prevents cells from attaching there.

Abstract: The present invention provides wood preservative composition containing a dispersed and/or emulsified phase comprising a wood preservative component; and a stabilizer. The stabilizer is a cationic polymer, an enzyme, organic polymer, quaternary ammonium compound and/or a mixture thereof. Also provided is a method of preserving wood or other cellulosic material which comprises applying to the wood or other cellulosic material.

Abstract: This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.

Abstract: Disclosed is the use of isothiocyanate compounds. In particular, disclosed is the use of a compound as shown by Formula (I) or a derivative as shown by Formula (II) in the manufacture of a composition or preparation for preventing and/or treating hyperlipidemia. The compound of the present invention can reduce the levels of triglycerides and low density lipoproteins in the serum of mammals (such as rats and humans), increase the level of high density lipoproteins in the serum, and reduce the level of total bilirubin in the serum of mammals (such as rats and humans).

Abstract: The present disclosure relates to the provision of novel biodegradable amphiphilic peptides and peptide analogues based derivatives comprising hydrophobic chains and their use in the permeabilization of mammalian cells and delivery of agents, for example therapeutic agents, imaging agents and cell preservation agents.

Abstract: The present disclosure provides methods for determining an etiology of upper and/or lower eyelid puffiness by examining a subject with squinted eyes; and determining if upper and/or lower eyelid puffiness does not improve, improves, partially improves, or worsens, wherein the etiology of the upper and/or lower eyelid puffiness is diagnosed to be anterior to the orbicularis oculi muscle if the puffiness does not improve, wherein the etiology of the upper and/or lower eyelid puffiness is determined to be posterior to the orbicularis oculi muscle if the puffiness improves, wherein the etiology of the upper and/or lower eyelid puffiness is determined to be anterior and posterior to the orbicularis oculi muscle if the puffiness partially improves, or wherein the puffiness is determined to be secondary to hypertrophy of the orbicularis muscle or if the puffiness worsens.

Abstract: The present invention relates to a novel process for biological detection of mycobacteria via electrochemical analysis methods of the catalytic activity of antigen 85.

Abstract: The invention surprisingly found that Lactobacillus plantarum subsp. plantarum PS128 provides an advantageous effect in treatment or prevention of tic disorders and basal ganglia disorders. Accordingly, the invention provides a method of treating or preventing a movement disorder in a subject, comprising administering to a subject an effective amount of cells of a Lactobacillus plantarum subsp. plantarum PS128, which is deposited under DSMZ Accession No. DSM 28632.

Abstract: The present application relates to a freeze-dried polymer composition containing chitosan and at least one lyoprotectant, a process for preparing a freeze-dried composition containing chitosan and at least one lyoprotectant and the use of a reconstituted freeze-dried chitosan composition to prepare implants for tissue repair.

Abstract: An enzymatic processing plant for continuous flow-based enzymatic processing of organic molecules. The enzymatic processing plant including an enzymatic processing area, wherein the enzymatic processing area includes a turbulence-generating pipe with a repeatedly changing centre-line and/or a repeatedly changing cross-section, for generating turbulence to mix a reaction mixture and prevent sedimentation of particles as the reaction mixture is flowing through the turbulence-generating pipe. The enzymatic processing plant and the enzymatic processing area are arranged such that the reaction mixture is subjected to turbulence within the enzymatic processing area for a reaction time of 15 minutes or more.

Abstract: The present invention relates to the production of activated biological molecules for use in profiling biological molecule interactions. The activated biological molecule may be a ubiquitin (Ub) and ubiquitin-like conjugation enzyme as well as other proteins with internal reactive cysteine residues.

Abstract: Disclosed are compositions, medical devices and methods for ameliorating sterile injury due object use in a subject in need thereof. More particularly, the present disclosure relates to compositions including N-Acetylcysteine and an aminoquinoline. The present disclosure also relates to compositions including an endonuclease and an aminoquinoline. The present disclosure also relates to medical devices including a coating comprising N-Acetylcysteine, an aminoquinoline, an endonuclease, and combinations thereof.

Abstract: A method of producing lactic acid or a salt or an ester thereof, which includes incubating lignocellulosic hydrolysates in the presence of cells of an isolated strain of Thermoanaerobactor at a temperature above 70 degrees Celsius, wherein the Thermoanaerobactor comprises a 16S rDNA sequence at least 99% identical to the nucleic acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, and SEQ ID NO.

Abstract: Process are provided which are effective for controlling medium conductivity during fermentation of a CO-containing gaseous substrate while providing an STY of about 10 g ethanol/(L·day) or more. The process includes balancing medium conductivity, specific carbon uptake or cell density levels.

Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.